Canton Strategic Holdings (CNTN) Total Current Liabilities (2020 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Total Current Liabilities came in at $1.1 million in Q1 2026, down 53.9% YoY from $2.5 million in Q1 2025, and down 65.27% on a QoQ basis from $3.3 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 7 years of Total Current Liabilities data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 53.9% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 53.9% YoY) and the FY2025 annual result came in at $3.3 million, up 36.14% from the prior year.
- Total Current Liabilities fell to $1.1 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $3.3 million in Q4 2025 to a low of $902348.0 in Q3 2022.
- A 5-year average of $1.8 million and a median of $1.6 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 74.75% — and 2023, when it soared 58.52%.
- Tracing CNTN's Total Current Liabilities over 5 years: stood at $1.1 million in 2022, then soared by 58.52% to $1.8 million in 2023, then surged by 33.0% to $2.4 million in 2024, then soared by 36.14% to $3.3 million in 2025, then plunged by 65.27% to $1.1 million in 2026.
- The last three Total Current Liabilities figures came in at $1.1 million (Q1 2026), $3.3 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 2.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.63 Mn |
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.41 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 1.52 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 902,348.00 |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 4.53 Mn |
| Dec 31, 2020 | 2.73 Mn |